Skip to content
Study details
Enrolling now

Pyridostigmine for the Treatment of Constipation in Parkinson Disease

University of Vermont Medical Center
NCT IDNCT05603715ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Ages

18+

Locations

1 site in VT

About this study

This Phase 2 study is testing Pyridostigmine Bromide in people with constipation.

Based on ClinicalTrials.gov records.

PhasePhase 2
DrugPyridostigmine Bromide
Routeinjection

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low10%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Drug classes

Antimyasthenic Agents (Cholinesterase Inhibitors)

Drug routes

injection

Endpoints

Secondary: Changes from Baseline to the End of Study Visit in Beck Depression Inventory-II (BDI-II), Changes from Baseline to the End of Study Visit in the Gastrointestinal Dysfunction Scale in Parkinson's Disease (GIDS-PD), Changes from Baseline to the End of Study Visit in the MDS-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts I-IV, Number of adverse events and serious adverse events that occur during the trial

Body systems

Neurology, Gastroenterology